Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.

Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R.

PLoS One. 2019 Jul 18;14(7):e0218444. doi: 10.1371/journal.pone.0218444. eCollection 2019.

2.

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Dragani M, Rege-Cambrin G, Ferrero D, Abruzzese E, Pregno P, Elena C, Cedrone M, Santoro M, Andreani G, Saglio G, Fava C.

Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103. [Epub ahead of print] No abstract available.

PMID:
31161827
3.

Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 May 2. pii: haematol.2019.222059. doi: 10.3324/haematol.2019.222059. [Epub ahead of print]

4.

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.

Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1.

PMID:
31044260
5.

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M.

Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

PMID:
31029498
6.

Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series.

Michelerio A, Grassi S, Elena C, Croci GA, Boveri E, Bossi G, Brazzelli V.

Eur J Dermatol. 2019 Apr 1;29(2):174-178. doi: 10.1684/ejd.2019.3532.

PMID:
30973331
7.

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Bono E, McLornan D, Travaglino E, Gandhi S, Gallì A, Khan AA, Kulasekararaj AG, Boveri E, Raj K, Elena C, Ireland RM, Bianchessi A, Jiang J, Todisco G, Ferretti VV, Cazzola M, Marsh JCW, Malcovati L, Mufti GJ.

Leukemia. 2019 Apr 2. doi: 10.1038/s41375-019-0457-1. [Epub ahead of print]

PMID:
30940907
8.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Mar 20. doi: 10.1002/hon.2606. [Epub ahead of print]

PMID:
30892724
9.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

10.

Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.

Elena C, Chiara M, Angelica B, Chiara MA, Laura N, Chiara C, Claudio C, Antonella F, Nicola G.

Curr Pharm Biotechnol. 2018;19(15):1210-1220. doi: 10.2174/1389201020666190102145305. Review.

PMID:
30605054
11.

Low occurrence of hemosporidian parasites in the Neotropic cormorant (Phalacrocorax brasilianus) in Chile.

Pedro R, Claudio N, Elena C, Claudio V.

Parasitol Res. 2019 Jan;118(1):325-333. doi: 10.1007/s00436-018-6146-6. Epub 2018 Nov 17.

PMID:
30448937
12.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, Bonifacio M, Bonadonna P, Gleixner KV, Hadzijusufovic E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David Fuchs, Greul R, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niedoszytko M, Niederwieser D, Malcovati L, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Kluin-Nelemans H, Sperr WR; Study Group of the European Competence Network on Mastocytosis (ECNM).

J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87. doi: 10.1016/j.jaip.2018.09.024. Epub 2018 Nov 8. Review.

PMID:
30416055
13.

The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry.

Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Neri I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Di Stefano M, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M.

Future Oncol. 2018 Nov;14(26):2713-2723. doi: 10.2217/fon-2018-0291. Epub 2018 Sep 12.

PMID:
30207489
14.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

15.

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab.

Giuseppe P, Nicola P, Valentina C, Elena C, Salvatrice C, Rosario G, Rita BM.

Ann Dermatol. 2018 Aug;30(4):462-464. doi: 10.5021/ad.2018.30.4.462. Epub 2018 Jun 27.

16.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

17.

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.

Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, Moretta A, Cazzola M, Elena C, Vinti L, Locatelli F, Bottino C, Castriconi R.

J Immunol. 2017 Aug 15;199(4):1516-1525. doi: 10.4049/jimmunol.1601695. Epub 2017 Jul 12.

18.

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.

Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S.

Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017 Jun 16.

19.

Clinical significance of somatic mutation in unexplained blood cytopenia.

Malcovati L, Gallì A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, Elena C, Ferretti VV, Catricalà S, Bono E, Todisco G, Bianchessi A, Rumi E, Zibellini S, Pietra D, Boveri E, Camaschella C, Toniolo D, Papaemmanuil E, Ogawa S, Cazzola M.

Blood. 2017 Jun 22;129(25):3371-3378. doi: 10.1182/blood-2017-01-763425. Epub 2017 Apr 19.

20.

Phenotype of mutations in the promoter region of the β-globin gene.

Ropero P, Erquiaga S, Arrizabalaga B, Pérez G, de la Iglesia S, Torrejón MJ, Gil C, Elena C, Tenorio M, Nieto JM, de la Fuente-Gonzalo F, Villegas A, González Fernández FA, Martínez R.

J Clin Pathol. 2017 Oct;70(10):874-878. doi: 10.1136/jclinpath-2017-204378. Epub 2017 Apr 6.

PMID:
28385923
21.

Development of a highly efficient oil degumming process using a novel phosphatidylinositol-specific phospholipase C enzyme.

Cerminati S, Eberhardt F, Elena CE, Peirú S, Castelli ME, Menzella HG.

Appl Microbiol Biotechnol. 2017 Jun;101(11):4471-4479. doi: 10.1007/s00253-017-8201-0. Epub 2017 Feb 25.

PMID:
28238084
22.

Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.

Orlandi EM, Elena C, Bono E.

Leuk Lymphoma. 2017 Jul;58(7):1764-1766. doi: 10.1080/10428194.2016.1260127. Epub 2016 Nov 28. No abstract available.

PMID:
27892750
23.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M.

Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030. Epub 2016 Jul 6.

24.

'Real-life' study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis.

Merante S, Ferretti V, Elena C, Calvello C, Rocca B, Zappatore R, Cavigliano P, Orlandi E.

Hematology. 2017 Jan;22(1):1-8. Epub 2016 Jun 19.

PMID:
27320082
25.

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G.

Support Care Cancer. 2016 Nov;24(11):4487-93. doi: 10.1007/s00520-016-3286-z. Epub 2016 Jun 3.

PMID:
27260015
26.

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.

Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfì F, Salerno R, Fanelli T, Gesullo F, Corbizi Fattori G, Bonifacio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, Zanotti R.

Am J Hematol. 2016 Jul;91(7):692-9. doi: 10.1002/ajh.24382. Epub 2016 Jun 2.

27.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G.

Sci Rep. 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Erratum in: Sci Rep. 2016;6:22205. multiple author names corrected.

28.

Current and Novel Aspects on the Non-lysosomal β-Glucosylceramidase GBA2.

Massimo A, Maura S, Nicoletta L, Giulia M, Valentina M, Elena C, Alessandro P, Rosaria B, Sandro S.

Neurochem Res. 2016 Feb;41(1-2):210-20. doi: 10.1007/s11064-015-1763-2. Epub 2015 Nov 24. Review. Erratum in: Neurochem Res. 2016 Feb;41(1-2):221.

PMID:
26603294
29.

High-level production of Bacillus cereus phospholipase C in Corynebacterium glutamicum.

Ravasi P, Braia M, Eberhardt F, Elena C, Cerminati S, Peirú S, Castelli ME, Menzella HG.

J Biotechnol. 2015 Dec 20;216:142-8. doi: 10.1016/j.jbiotec.2015.10.018. Epub 2015 Oct 28.

PMID:
26519562
30.

Ophthalmological implications of the chronic infections with the hepatitis C Virus.

Anisia-Iuliana A, Alina C, Elena CR, Dorin C.

Rom J Ophthalmol. 2015 Oct-Dec;59(4):263-268.

31.

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Iurlo A, Orsi E, Cattaneo D, Resi V, Bucelli C, Orofino N, Sciumè M, Elena C, Grancini V, Consonni D, Orlandi EM, Cortelezzi A.

Oncotarget. 2015 Oct 20;6(32):33944-51. doi: 10.18632/oncotarget.5580.

32.

The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications.

Malcovati L, Ambaglio I, Elena C.

Curr Opin Oncol. 2015 Nov;27(6):551-9. doi: 10.1097/CCO.0000000000000229. Review.

PMID:
26352542
33.

Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis.

Orlandi EM, Elena C, Zibellini S.

Leuk Res Rep. 2015 Jul 17;4(2):45-6. doi: 10.1016/j.lrr.2015.05.003. eCollection 2015.

34.

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.

Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R, Gambacorti-Passerini C.

Am J Hematol. 2015 Oct;90(10):910-4. doi: 10.1002/ajh.24120. Epub 2015 Sep 10.

35.

Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.

Pecci A, Necchi V, Barozzi S, Vitali A, Boveri E, Elena C, Bernasconi P, Noris P, Solcia E.

J Hematol Oncol. 2015 Jun 18;8:71. doi: 10.1186/s13045-015-0169-6.

36.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E.

Blood. 2015 Jul 9;126(2):233-41. doi: 10.1182/blood-2015-03-633537. Epub 2015 May 8.

37.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T.

Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.

PMID:
25130523
38.

Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia.

Brazzelli V, Grasso V, Elena C, Orlandi E, Borroni G.

G Ital Dermatol Venereol. 2015 Oct;150(5):623-5. Epub 2014 Jul 11. No abstract available.

PMID:
25014583
39.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallì A, Della Porta MG, Travaglino E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M.

Blood. 2014 Aug 28;124(9):1513-21. doi: 10.1182/blood-2014-03-560227. Epub 2014 Jun 26.

40.

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via' MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda (REL) Clinical Network.

Leukemia. 2015 Jan;29(1):66-75. doi: 10.1038/leu.2014.161. Epub 2014 May 20.

PMID:
24935723
41.

Effect of systemic inflammation on level of ferritin seminal in chronic renal male patient undergoing hemodialysis.

Silva GP, Elena CDV, Carneiro FP, Veiga JPR.

Int Arch Med. 2014 May 12;7:23. doi: 10.1186/1755-7682-7-23. eCollection 2014.

42.

Expression of codon optimized genes in microbial systems: current industrial applications and perspectives.

Elena C, Ravasi P, Castelli ME, Peirú S, Menzella HG.

Front Microbiol. 2014 Feb 4;5:21. doi: 10.3389/fmicb.2014.00021. eCollection 2014. Review.

43.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

44.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

45.

Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.

Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, Polverelli N, Ruggeri M, Vannucchi AM, Antonioli E, Lussana F, Tieghi A, Iurlo A, Elli E, Ruella M, Fabris F, Cazzola M, Barbui T.

Am J Hematol. 2014 Mar;89(3):306-9. doi: 10.1002/ajh.23635. Epub 2014 Feb 19.

46.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Cancer. 2014 Feb 15;120(4):513-20.

47.

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

Klampfl T, Milosevic JD, Puda A, Schönegger A, Bagienski K, Berg T, Harutyunyan AS, Gisslinger B, Rumi E, Malcovati L, Pietra D, Elena C, Della Porta MG, Pieri L, Guglielmelli P, Bock C, Doubek M, Dvorakova D, Suvajdzic N, Tomin D, Tosic N, Racil Z, Steurer M, Pavlovic S, Vannucchi AM, Cazzola M, Gisslinger H, Kralovics R.

PLoS One. 2013 Oct 16;8(10):e77819. doi: 10.1371/journal.pone.0077819. eCollection 2013.

48.

Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo.

Lisbeth M, Consuelo P, Glenda C, Elena C, Carlos RJ, Alejandro R, Maria GY.

Curr Drug Deliv. 2013 Jun;10(3):343-7.

PMID:
23808594
49.

L28. Relevance of detection techniques for ANCA testing.

Elena C.

Presse Med. 2013 Apr;42(4 Pt 2):582-4. doi: 10.1016/j.lpm.2013.01.028. Epub 2013 Mar 6.

PMID:
23474049
50.

Clinical significance of genetic aberrations in secondary acute myeloid leukemia.

Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R.

Am J Hematol. 2012 Nov;87(11):1010-6. doi: 10.1002/ajh.23309. Epub 2012 Aug 7.

Supplemental Content

Support Center